325 related articles for article (PubMed ID: 17352682)
1. Prolyl peptidases related to dipeptidyl peptidase IV: potential of specific inhibitors in drug discovery.
Van der Veken P; Haemers A; Augustyns K
Curr Top Med Chem; 2007; 7(6):621-35. PubMed ID: 17352682
[TBL] [Abstract][Full Text] [Related]
2. Current advances and therapeutic potential of agents targeting dipeptidyl peptidases-IV, -II, 8/9 and fibroblast activation protein.
Chen SJ; Jiaang WT
Curr Top Med Chem; 2011; 11(12):1447-63. PubMed ID: 21510839
[TBL] [Abstract][Full Text] [Related]
3. Prolyl peptidases: a serine protease subfamily with high potential for drug discovery.
Rosenblum JS; Kozarich JW
Curr Opin Chem Biol; 2003 Aug; 7(4):496-504. PubMed ID: 12941425
[TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.
Lankas GR; Leiting B; Roy RS; Eiermann GJ; Beconi MG; Biftu T; Chan CC; Edmondson S; Feeney WP; He H; Ippolito DE; Kim D; Lyons KA; Ok HO; Patel RA; Petrov AN; Pryor KA; Qian X; Reigle L; Woods A; Wu JK; Zaller D; Zhang X; Zhu L; Weber AE; Thornberry NA
Diabetes; 2005 Oct; 54(10):2988-94. PubMed ID: 16186403
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of dipeptidyl peptidase 8/9 impairs preadipocyte differentiation.
Han R; Wang X; Bachovchin W; Zukowska Z; Osborn JW
Sci Rep; 2015 Aug; 5():12348. PubMed ID: 26242871
[TBL] [Abstract][Full Text] [Related]
6. Expression pattern of dipeptidyl peptidase IV activity and/or structure homologues in cancer.
Kotacková L; Baláziová E; Sedo A
Folia Biol (Praha); 2009; 55(3):77-84. PubMed ID: 19545486
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?
Juillerat-Jeanneret L
J Med Chem; 2014 Mar; 57(6):2197-212. PubMed ID: 24099035
[TBL] [Abstract][Full Text] [Related]
8. Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Thornberry NA; Weber AE
Curr Top Med Chem; 2007; 7(6):557-68. PubMed ID: 17352677
[TBL] [Abstract][Full Text] [Related]
9. Role of a propeller loop in the quaternary structure and enzymatic activity of prolyl dipeptidases DPP-IV and DPP9.
Tang HK; Chen KC; Liou GG; Cheng SC; Chien CH; Tang HY; Huang LH; Chang HP; Chou CY; Chen X
FEBS Lett; 2011 Nov; 585(21):3409-14. PubMed ID: 22001206
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in non-peptidomimetic dipeptidyl peptidase 4 inhibitors: medicinal chemistry and preclinical aspects.
Liu Y; Hu Y; Liu T
Curr Med Chem; 2012; 19(23):3982-99. PubMed ID: 22709010
[TBL] [Abstract][Full Text] [Related]
11. Substituted 4-carboxymethylpyroglutamic acid diamides as potent and selective inhibitors of fibroblast activation protein.
Tsai TY; Yeh TK; Chen X; Hsu T; Jao YC; Huang CH; Song JS; Huang YC; Chien CH; Chiu JH; Yen SC; Tang HK; Chao YS; Jiaang WT
J Med Chem; 2010 Sep; 53(18):6572-83. PubMed ID: 20718420
[TBL] [Abstract][Full Text] [Related]
12. Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries.
Matheeussen V; Baerts L; De Meyer G; De Keulenaer G; Van der Veken P; Augustyns K; Dubois V; Scharpé S; De Meester I
Biol Chem; 2011 Mar; 392(3):189-98. PubMed ID: 21194356
[TBL] [Abstract][Full Text] [Related]
13. Crystal structures of a bacterial dipeptidyl peptidase IV reveal a novel substrate recognition mechanism distinct from that of mammalian orthologues.
Roppongi S; Suzuki Y; Tateoka C; Fujimoto M; Morisawa S; Iizuka I; Nakamura A; Honma N; Shida Y; Ogasawara W; Tanaka N; Sakamoto Y; Nonaka T
Sci Rep; 2018 Feb; 8(1):2714. PubMed ID: 29426867
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, structure-activity relationships, and docking studies of 1-(γ-1,2,3-triazol substituted prolyl)-(S)-3,3-difluoropyrrolidines as a novel series of potent and selective dipeptidyl peptidase-4 inhibitors.
Zhang L; Su M; Li J; Ji X; Wang J; Li Z; Li J; Liu H
Chem Biol Drug Des; 2013 Feb; 81(2):198-207. PubMed ID: 22994702
[TBL] [Abstract][Full Text] [Related]
15. Expression of dipeptidyl peptidase-IV activity and/or structure homologs in human meningiomas.
Stremenová J; Mares V; Lisá V; Hilser M; Krepela E; Vanicková Z; Syrucek M; Soula O; Sedo A
Int J Oncol; 2010 Feb; 36(2):351-8. PubMed ID: 20043068
[TBL] [Abstract][Full Text] [Related]
16. Cloning and characterization of dipeptidyl peptidase 10, a new member of an emerging subgroup of serine proteases.
Qi SY; Riviere PJ; Trojnar J; Junien JL; Akinsanya KO
Biochem J; 2003 Jul; 373(Pt 1):179-89. PubMed ID: 12662155
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous (19)F NMR screening of prolyl oligopeptidase and dipeptidyl peptidase IV inhibitors.
Kichik N; Tarragó T; Giralt E
Chembiochem; 2010 May; 11(8):1115-9. PubMed ID: 20397181
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes.
Drucker DJ
Expert Opin Investig Drugs; 2003 Jan; 12(1):87-100. PubMed ID: 12517256
[TBL] [Abstract][Full Text] [Related]
19. The prolyl-aminodipeptidases and their inhibitors as therapeutic targets for fibrogenic disorders.
Juillerat-Jeanneret L; Gerber-Lemaire S
Mini Rev Med Chem; 2009 Feb; 9(2):215-26. PubMed ID: 19200026
[TBL] [Abstract][Full Text] [Related]
20. Activity and selectivity cliffs for DPP-IV inhibitors: Lessons we can learn from SAR studies and their application to virtual screening.
Ojeda-Montes MJ; Gimeno A; Tomas-Hernández S; Cereto-Massagué A; Beltrán-Debón R; Valls C; Mulero M; Pujadas G; Garcia-Vallvé S
Med Res Rev; 2018 Sep; 38(6):1874-1915. PubMed ID: 29660786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
